SARMs vs peptides on TikTok: separating hype from hard data

What's this video probably claiming?

The caption references SARMs (selective androgen receptor modulators) with a coy emoji and satire hashtags, suggesting @noahphysiquecoaching is either joking about using them, comparing them favorably to peptides, or doing the classic "not financial advice" deflection that fitness creators use to sidestep accountability. Given the video is categorized under peptide therapy, the likely angle is a comparison framing: peptides are the "safer" or "smarter" alternative to SARMs, or the creator is poking fun at the bodybuilding community's cavalier attitude toward both drug classes. This is a well-worn TikTok genre. The satire tag gives plausible deniability, but information embedded in satire still lands in people's heads and shapes real decisions about real compounds with real physiological effects.

What does the science actually show?

SARMs are not approved by the FDA for any medical use in humans. Full stop. Compounds like ostarine (MK-2866), ligandrol (LGD-4033), and RAD-140 were developed by pharmaceutical companies and largely abandoned or still in trials because of hepatotoxicity signals and endocrine suppression. A 2020 case series published in Drug and Chemical Toxicology documented liver injury in young men using ostarine purchased online. Bhasin et al. (2020, NEJM) reviewing androgen pharmacology noted that no SARM has cleared Phase III trials for muscle wasting or osteoporosis. Peptides like BPC-157 or CJC-1295 operate on entirely different receptor systems, but they also lack strong human RCT data. Comparing the two as if one is a validated clinical alternative to the other is not supported by current evidence in either direction.

Where does the social media noise diverge from clinical reality?

The gym-TikTok version of pharmacology runs on anecdote and before-and-after photos. SARMs get framed as "steroids lite" with all the muscle and none of the side effects, which contradicts what we actually see in case reports. A 2021 review in British Journal of Clinical Pharmacology (Nass et al.) found testosterone suppression in male SARMs users significant enough to require post-cycle therapy in some cases, which is ironically the same problem users are trying to avoid. On the peptide side, compounds like ipamorelin and CJC-1295 are routinely described online as risk-free growth hormone secretagogues. The reality is that long-term IGF-1 elevation from any source carries theoretical oncology risk, and the available human data on these peptide combinations is thin. Neither category deserves the breezy treatment satire content tends to give it.

What should you actually know?

If you are watching this video and wondering whether SARMs are safer than steroids, or whether peptides are safer than SARMs, here is the honest answer: we do not have the long-term human data to rank them confidently. SARMs are sold legally as "research chemicals" but marketed to bodybuilders, a regulatory gray area the FDA has repeatedly flagged. The agency issued warnings in 2017 and again in 2023 about contaminated and mislabeled SARM products. Peptides exist in a different regulatory category, with some available through compounding pharmacies under provider supervision. That distinction matters. Getting peptide therapy through a licensed provider with lab monitoring is categorically different from ordering SARMs from a supplement website. Anyone treating these as equivalent decisions is missing a meaningful layer of risk stratification. Satire or not, framing both casually does real harm to real people making real health decisions.